Therapeutic Goods Administration (TGA)
We are Australia's government authority responsible for evaluating, assessing and monitoring products that are defined as therapeutic goods. We regulate medicines, medical devices and biologicals to help Australians stay healthy and safe.
- Pholcodine cough medicines recall collectionRead alerts and updates about the 2023 cancellation and recall of pholcodine cough medicines.
- COVID-19 rapid antigen self-tests that are approved in AustraliaA list of approved COVID-19 tests included in the ARTG for supply in Australia.
- MDMA and psilocybinAuthorised psychiatrists can prescribe MDMA and psilocybin for specific mental health conditions from 1 July 2023.
Search for health products on our register
Search the Australian Register of Therapeutic Goods (ARTG) by name, ID or sponsor. Search results from the ARTG include Consumer Medicines Information (CMI) and Product Information (PI). Not all CMI and PI documents are available on this website.
Frequently searched by industry
Frequently searched by health professionals
- Substitution instrument to address shortage of COUMADIN warfarin 5mg tabletsAs the shortage of Coumadin 5mg tablets is expected to continue, the TGA has made a Serious Scarcity Substitution Instrument to assist patients to access their medicine from their pharmacist without delay or interruption to treatment.
- PholcodineThe TGA has decided to cancel the registration of pholcodine-containing medicines and is recalling them from pharmacies.
- Curash Nappy Rash CreamChurch and Dwight are recalling two batches of Curash Nappy Rash Cream, following reports of adverse reactions
Latest news and updates
- TGA’s new powers will help reduce the impact of medicine shortages on patientsFrom 22 March 2023 changes to the Therapeutic Goods Act 1989 will help alleviate the effects of medicine shortages on patients.
- COVID-19 vaccine safety report - 23-03-2023Information about the TGA's safety monitoring of COVID-19 vaccines.
- Lapse of provisional registration for Tecentriq (atezolizumab) for the treatment of locally advanced or metastatic triple negative breast cancer (mTNBC)Provisional registration of Tecentriq (atezolizumab) for the treatment in mTNBC will lapse on 22 March 2023.